Intra-cellular Therapies v. MSN Laboratories: Lumateperone Patent Case Consolidated
Intra-cellular Therapies filed suit in the District of New Jersey asserting three patents covering CAPLYTA® (lumateperone) capsules against MSN Laboratories’ proposed generic. The case was consolidated into lead action No. 3:24-cv-04264 just 70 days after filing, signalling a coordinated multi-defendant ANDA litigation strategy.
Filing to Case Consolidated in 70 days
70 days — from filing to consolidation order in D.N.J.
Case consolidated: what the order means for CAPLYTA® patent litigation
Consolidation merges parallel ANDA cases into one proceeding
When multiple ANDA filers challenge the same branded drug, each triggers a separate Hatch-Waxman lawsuit. Courts routinely consolidate these actions into a lead case to avoid duplicative discovery and inconsistent rulings. Here, this action was folded into No. 3:24-cv-04264, where all substantive litigation — claim construction, expert reports, and trial — will proceed. Consolidation is procedural; no patent claims have been adjudicated.
Procedural — no merits rulingIntra-cellular Therapies gains litigation efficiency across ANDA defendants
Consolidation typically benefits the brand patentee by centralising case management, reducing duplicative costs, and enabling a single consistent record. Intra-cellular Therapies’ three patents remain fully asserted. Pro hac vice admissions carry over automatically, preserving continuity of counsel. The 30-month Hatch-Waxman stay of FDA approval continues to run in the lead action.
Patents remain assertedMSN Laboratories now litigates alongside other generic filers
MSN Laboratories will defend in the consolidated proceeding alongside any other ANDA filers named in the lead action. Consolidated discovery can expose each defendant’s ANDA product details to co-defendants, which may create strategic tensions. However, MSN retains its own invalidity and non-infringement arguments — consolidation does not merge defences or bind defendants to each other’s positions.
Defences intact; shared forumLumateperone market entry timeline tied to lead case resolution
CAPLYTA® generated substantial revenues for Intra-cellular Therapies. Consolidation means generic market entry for all named defendants — including MSN — will depend on the outcome of a single coordinated trial. A finding of infringement and validity in the lead action would block all consolidated defendants simultaneously, extending brand exclusivity and protecting the lumateperone franchise across dosage strengths.
Generic entry gated on lead caseFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Intra-cellular Therapies, Inc. | Company | Search in Eureka ↗ |
| Defendant | MSN Laboratories Private, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Katelyn O’Reilly | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lauren Ruth Malakoff | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Intra-cellular Therapies, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is procedural rather than substantive — it transfers active litigation into a lead docket and extends pro hac vice admissions, but makes no finding on infringement, validity, or enforceability of the three asserted lumateperone patents. The phrasing ‘deemed admitted pro hac vice in Civil Action No. 3:24-cv-04264’ confirms that counsel continuity is preserved. Practitioners should note that all merits rulings will now appear on the lead case docket, not this filing number.
US12128043B2, US12122792B2 & US12090155B2 — lumateperone capsule formulations
The three patents-in-suit — US12128043B2, US12122792B2, and US12090155B2 — all relate to lumateperone, the active ingredient in CAPLYTA®, a dopamine and serotonin receptor modulator approved for schizophrenia and bipolar depression. The application numbers (US18/602981, US18/240951, US18/494754) suggest these patents were prosecuted recently, potentially as continuation or divisional filings designed to extend protection over specific formulation parameters across the 10.5 mg, 21 mg, and 42 mg capsule strengths at issue.
For the CNS drug sector, lumateperone’s multi-receptor mechanism represents a differentiated pharmacological profile, and protecting that profile through layered formulation patents is a commercially rational strategy. Generic manufacturers targeting CAPLYTA® must navigate all three patents simultaneously. The prosecution history of each application — particularly any distinctions made over prior art during examination — will be critical to claim construction and invalidity arguments in the lead consolidated action.
Should you run an FTO against US12128043B2, US12122792B2 & US12090155B2?
Any pharmaceutical company developing a generic or follow-on lumateperone capsule product should conduct a formal freedom-to-operate analysis against all three patents before filing an ANDA or advancing formulation development. The patents collectively cover capsule formulations at the specific dosage strengths sold as CAPLYTA® — meaning even minor reformulation may not be sufficient to avoid the claims without a thorough claim-by-claim mapping against your product specifications.
PatSnap Eureka’s FTO Search Agent can map your lumateperone formulation parameters against the claim language of US12128043B2, US12122792B2, and US12090155B2 in minutes. Eureka surfaces related prosecution history, identifies continuations-in-prosecution that may generate additional blocking patents, and benchmarks your product against the prior art cited during examination — giving your IP and R&D teams the structured intelligence needed to make informed go/no-go decisions on ANDA filings.
Run a freedom-to-operate analysis on US12128043B2 to assess your product’s exposure
Run FTO in Eureka →Similar lumateperone & CNS drug ANDA patent cases in D.N.J.
Explore consolidated Hatch-Waxman actions involving CNS formulation patents in the District of New Jersey, including other CAPLYTA® and atypical antipsychotic cases.
What this case signals for the branded CNS drug IP landscape
CAPLYTA® consolidation reflects the standard Hatch-Waxman playbook — but the three-patent stack and multi-defendant structure raise the litigation stakes.
Three-patent assertion broadens the validity risk surface for generics
Asserting three separate patents — US12128043B2, US12122792B2, and US12090155B2 — against lumateperone capsules means generic challengers must invalidate or design around all three to achieve freedom to operate. Each patent likely covers distinct aspects of the formulation, creating layered exclusivity that is structurally harder to overcome than a single-patent assertion.
Rapid consolidation suggests multiple ANDA filers targeted CAPLYTA®
A consolidation order issued just 70 days after filing strongly suggests that Intra-cellular Therapies had already filed — or anticipated — parallel actions against additional generic applicants. IP teams monitoring CNS drug pipelines should track the lead action No. 3:24-cv-04264 as the single docket that will resolve generic entry risk for lumateperone across all dosage forms.
Intra-cellular v MSN — key questions answered
The case was consolidated into lead action No. 3:24-cv-04264 after 70 days. No merits ruling on infringement or validity was issued. All counsel admitted pro hac vice in this action were deemed admitted in the lead consolidated proceeding. The three lumateperone patents remain fully asserted.
Intra-cellular Therapies asserted US12128043B2 (application US18/602981), US12122792B2 (application US18/240951), and US12090155B2 (application US18/494754), all covering lumateperone capsule formulations corresponding to CAPLYTA® 10.5 mg, 21 mg, and 42 mg dosage strengths.
Consolidation merges parallel ANDA actions involving the same branded drug into a single lead docket. Discovery, claim construction, and trial proceed jointly. Each defendant retains its own invalidity and non-infringement positions, but the case is managed by one judge under a unified schedule. It does not constitute a merits ruling on any patent claim.
Consolidation is a procedural mechanism and does not independently modify the 30-month stay triggered by Intra-cellular Therapies’ timely infringement suit. The stay continues to run in the lead action. MSN Laboratories cannot receive final FDA approval for its generic lumateperone capsules until the stay expires or a court rules in its favour, whichever comes first.
CAPLYTA® (lumateperone) is an atypical antipsychotic approved for schizophrenia and bipolar I and II depression, marketed by Intra-cellular Therapies. Its multi-receptor mechanism differentiates it from older antipsychotics. Given its commercial revenues, blocking generic entry through patent litigation is a high-value enforcement priority, making the outcome of the consolidated lead action significant for both brand and generic manufacturers.
PatSnap Eureka searches patents and litigation data to answer instantly.